PUBLIC COMPANY
save$MDGLMADRIGAL PHARMACEUTICALS, INC.
$MDGL431.00-2.12%West Conshohocken, PA, USupdated 19d ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase4Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
- phase1Resmetirom in Patients With MASH and HFpEF
- phase2Study of Resmetirom in Children and Adolescents With MASH
- phase3A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
- phase2Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
- —Rezdiffra Pregnancy and Lactation Registry
- phase2Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
- phase2Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
🐶 Hiring Signal
News
- Rasonque sales drive RevMed's stock; whistleblower sues Madrigal over MASHPlus news about Rezera, ANI Pharmaceuticals, Cloudbreak Pharma and Anaheim Bio. RevMed’s stock jumps on early Rasonque sales: The RAS drug developer reported sales of its pancreatic cancer therapy…endpoints · 11d ago
- A treatment revolution is underway in MASHTo build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patie…biospace · 12d ago
- STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drugA top former executive at Madrigal Pharmaceuticals has filed a lawsuit in federal court alleging a coverup of drug safety issues.stat · 12d ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 6mo ago
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that